These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 22965051)
1. Teva v. AstraZeneca and secret prior art under 102(g)(2). Lee S; Knierim M Nat Biotechnol; 2012 Sep; 30(9):831-3. PubMed ID: 22965051 [No Abstract] [Full Text] [Related]
2. Litgation over for AstraZeneca’s Crestor® drug. Sklan A Pharm Pat Anal; 2013 May; 2(3):301. PubMed ID: 24386659 [No Abstract] [Full Text] [Related]
3. The statin wars: why AstraZeneca must retreat. Lancet; 2003 Oct; 362(9393):1341. PubMed ID: 14585629 [No Abstract] [Full Text] [Related]
6. Supreme Court of India rejects Novartis’ cancer drug patent. Heseltine P Pharm Pat Anal; 2013 May; 2(3):299-300. PubMed ID: 24237056 [No Abstract] [Full Text] [Related]
7. Nonobviousness of pharmaceutical inventions: implications for patent prosecution and litigation. Dhulap S; Kulkarni M Pharm Pat Anal; 2019 Jul; 8(4):91-107. PubMed ID: 31414965 [TBL] [Abstract][Full Text] [Related]
8. Must an inventor "possess" an invention to patent it? Woessner WD; Chadwick RA Cold Spring Harb Perspect Med; 2014 Sep; 4(11):a020867. PubMed ID: 25237144 [TBL] [Abstract][Full Text] [Related]
9. Statin utilisation--recognising the role of the invisible hand. Minhas R Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171 [No Abstract] [Full Text] [Related]
12. Intellectual property. Judge turns Rochester's golden patent into lead. Malakoff D Science; 2003 Mar; 299(5613):1638-9. PubMed ID: 12637705 [No Abstract] [Full Text] [Related]
13. Two more drugs for dyslipidemia. Roberts WC Am J Cardiol; 2004 Mar; 93(6):809-11. PubMed ID: 15019903 [No Abstract] [Full Text] [Related]
14. Patent border wars: defining the boundary between scientific discoveries and patentable inventions. Holman CM Trends Biotechnol; 2007 Dec; 25(12):539-43. PubMed ID: 17983675 [TBL] [Abstract][Full Text] [Related]
15. Public health. U.S. panel favors wider use of preventive drug treatment. Couzin-Frankel J Science; 2010 Jan; 327(5962):130-1. PubMed ID: 20056859 [No Abstract] [Full Text] [Related]
16. Was the FDA misled by JUPITER? MacDonald GP J Am Osteopath Assoc; 2010 Aug; 110(8):424-5. PubMed ID: 20805547 [No Abstract] [Full Text] [Related]
17. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents. Teitelbaum R; Cohen M Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990 [No Abstract] [Full Text] [Related]
18. Most would fail to benefit from JUPITER Intervention. Plonk WM J Am Coll Cardiol; 2009 Aug; 54(8):744; author reply 744-5. PubMed ID: 19679258 [No Abstract] [Full Text] [Related]
19. Trade secret protection in the pharma industry. Armstrong M Pharm Pat Anal; 2016 Sep; 5(5):285-8. PubMed ID: 27572950 [No Abstract] [Full Text] [Related]